Piramal Pharma Solutions, a unit of Indian CDMO Piramal Pharma, plans to spend $80 million to expand its sterile injectables ...

Phreesia has generated evidence that exposing patients to vaccine messages at the point of care boosts the vaccination rate, ...

Moderna has suffered its second PMCPA rebuke in quick succession. Days after ruling Moderna had brought discredit on the ...

After experiencing a series of ups and downs in recent years, the biopharma contracting business is gearing up for a rebound ...

Astellas Pharma is slowing things down in the inaugural consumer-facing marketing blast for eye disease drug Izervay. | ...

With its first approval in hand, privately held IntraBio is embarking upon the difficult task of marketing a drug for an ...

On Monday, SK revealed that it will spend $260 million to construct its fifth production site in its home country, this one ...

After putting on a strong performance in preventing disease progression in the earlier treatment of multiple myeloma, Johnson ...

Otsuka is once again on the PMCPA’s naughty list as the U.K. drug marketing regulatory body has for the second time this year ...

After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...

After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has ...

In the latest of several recent mpox vaccine supply deals, Bavarian Nordic plans to provide 1 million doses of its shot, ...